Reneo Pharmaceuticals to Present Preclinical Mavodelpar (REN001) Data at the Society for Inherited Metabolic Disorders Annual Meeting 2023

Rhea-AI Summary

Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) announced participation at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting in Salt Lake City from Mar. 18-21, 2023. The company will present a preclinical poster titled PPARδ Agonist REN001 Improves Mitochondrial Function in Skeletal Muscle on Mar. 19, highlighting studies on mavodelpar (REN001) as a selective PPARδ agonist that enhances fatty acid metabolism. Currently, mavodelpar is under evaluation in the pivotal clinical trial REN001-201 for patients with primary mitochondrial myopathies. The poster will be available on Reneo's website post-event.

IRVINE, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company will present a preclinical poster at the Society for Inherited Metabolic Disorders (SIMD) Annual Meeting, being held in Salt Lake City, Utah, Mar. 18-21, 2023.

Presentation
PPARδ Agonist REN001 Improves Mitochondrial Function in Skeletal Muscle: A Potential Treatment for Primary Mitochondrial Myopathies

Date and Time
Presenter: John Adams Ph.D., Senior Vice President, Translational Science
Session: Sunday, Mar. 19, 2023, from 7:00-10:00 p.m. MST

The poster highlights the findings of pharmacological and biochemical studies which demonstrate that mavodelpar (REN001) is a potent and selective agonist of peroxisome proliferator-activated receptor delta (PPARδ), resulting in increased fatty acid metabolism. Further, mavodelpar activation of PPARδ in mice was found to increase expression of genes involved in fatty acid metabolism, oxidative phosphorylation, and mitochondrial biogenesis.

Mavodelpar is currently being evaluated in a pivotal randomized controlled clinical trial, REN001-201 (STRIDE; NCT04535609) in adult patients with primary mitochondrial myopathies (PMM) with confirmed mitochondrial DNA (mtDNA) defects. The poster presentation will be available on the Presentations and Publications page of the Reneo Pharmaceuticals website following the event.

About Reneo Pharmaceuticals

Reneo is a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, which are often associated with the inability of mitochondria to produce adenosine triphosphate (ATP). Our lead product candidate, mavodelpar, is a potent and selective agonist of the peroxisome proliferator-activated receptor delta (PPARδ). Mavodelpar has been shown to increase transcription of genes involved in mitochondrial function and increase fatty acid oxidation (FAO), and may increase production of new mitochondria. For additional information, please see reneopharma.com.

About Mavodelpar

Mavodelpar (REN001) is a potent and selective peroxisome proliferator-activated receptor delta (PPARδ) agonist currently in clinical development for two rare genetic mitochondrial diseases that typically present with myopathy and have high unmet medical needs: primary mitochondrial myopathies (PMM) and long-chain fatty acid oxidation disorders (LC-FAOD). For additional information, please see clinicaltrials.gov.

About PMM

PMM are a group of rare, genetic metabolic disorders caused by mutations or deletions in the mitochondrial DNA (mtDNA) or nuclear DNA (nDNA). These genetic alterations hamper the ability of mitochondria to generate energy from nutrient sources, resulting in energy deficits that are most pronounced in tissues with high energy demand such as muscle, brain, and heart. The symptoms of PMM include muscle weakness, exercise intolerance, movement disorder, deafness, blindness, and droopy eyelids among others. The prognosis for these disorders ranges in severity from progressive weakness to death.

Forward-Looking Statements 

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include statements regarding, among other things, the completion of enrollment of clinical trials, announcement of topline data from the STRIDE study, and the submission of marketing applications. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “plans,” “will,” “believes,” “anticipates,” “expects,” “intends,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Reneo’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Reneo’s business in general, and the other risks described in Reneo’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Reneo undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. 

Contacts:

Danielle Spangler
Investor Relations
Reneo Pharmaceuticals, Inc.
dspangler@reneopharma.com

David Melamed, Ph.D.
Media Inquiries
Russo Partners, LLC
david.melamed@russopartnersllc.com

FAQ

What is Reneo Pharmaceuticals presenting at the SIMD Annual Meeting in 2023?

Reneo Pharmaceuticals is presenting a poster on PPARδ Agonist REN001 and its effects on mitochondrial function in skeletal muscle.

When is Reneo Pharmaceuticals' presentation at the SIMD Annual Meeting?

Reneo Pharmaceuticals' presentation will take place on Mar. 19, 2023, from 7:00-10:00 p.m. MST.

What is mavodelpar (REN001) being studied for?

Mavodelpar (REN001) is being studied for its potential to treat primary mitochondrial myopathies.

What are primary mitochondrial myopathies (PMM)?

PMM are rare genetic disorders caused by mitochondrial DNA mutations, leading to energy deficits in high-demand tissues.

Where can I find Reneo Pharmaceuticals' poster presentation after the SIMD event?

The poster presentation will be available on Reneo Pharmaceuticals' Presentations and Publications page after the event.